Last Updated : July 27, 2023
Details
Project Line:
Reimbursement Review
Project Sub Line:
Pharmaceutical Review Update
CADTH Program Updates
- Drug Reimbursement Reviews for COVID-19 Drugs
CADTH has received requests from participating public drug plans about reimbursement recommendations for existing and future COVID-19 drugs. The national procurement process for COVID-19 drugs was initially established to support Health Canada’s emergency authorizations and access through the Public Health Agency of Canada. However, it is assumed that access will eventually transition from a centralized process to the provinces and territories. In anticipation of this transition, and to support ongoing access to these products, sponsors can now submit drugs for COVID-19 to CADTH’s Drug Reimbursement Review program.
For more information on the drug reimbursement review process, please refer to the Procedures for CADTH Drug Reimbursement Reviews or submit questions to [email protected].
Last Updated : July 27, 2023
